National Lung Cancer Partnership 2008 Career Development Award Request for Applications Purpose of Award The award provides funding for clinical and basic science fellows and junior faculty to advance their careers in lung cancer etiology, prevention, early detection, treatment, and symptom management. The Career Development Award is intended to provide "protected time" for fellows and newly independent investigators to develop their careers in lung cancer research. Applications will be judged on the quality of the applicant’s research, feasibility of the Career Development Plan, and the resources and environment available to the applicant, including the ability of the primary mentor to provide appropriate guidance and protected time during the award period. The applicant should state in the application how this award would advance their career. The award will be provided for up to $50,000 per year ($100,000 maximum over 2 years). The award is designed to be used primarily for salary support, but can also be used for the support of research, including technical assistance, supplies or reagents. The award cannot be used to purchase major equipment for general use. It is the policy of National Lung Cancer Partnership not to provide indirect costs to the award recipient’s institution. Eligibility 1. At the time of application, an applicant must hold a doctoral degree (MD, PhD, DO, DrPH, or equivalent), and be a post-doctoral fellow or be in the first 5 years of a faculty appointment at a not-for-profit institution. Pre-doctoral fellows are not eligible for the Career Development Award. 2. Applications will only be accepted from individuals involved in lung cancer research. 3. Applications will be accepted from individuals at US and Canadian sponsoring institutions. The applicant need not be a citizen of either country. If the applicant is not a US or Canadian citizen, verification of work visa must be provided. 4. There must be a Primary Mentor at the applicant’s institution who will oversee the applicant’s Career Development Plan. The Primary Mentor may only support one applicant. 5. The Career Development Award recipient must spend a minimum of 50 percent of her/his time in lung cancer research. This time should be free from major patient care, teaching, administrative, or other responsibilities. 6. The Career Development Award recipient may not hold another fellowship or award designed for career development at the time the Award is granted. The Award recipient is encouraged to hold other grants to support research costs. 7. The Career Development Award recipient may not have knowingly received any research funding from the tobacco industry, its parent companies, or subsidiaries, within the last 5 years. 8. Applications involving animals must receive approval from the institution’s Animal Care and Use Committee before award commencement. 9. Applications involving human participants must receive approval from the local Institutional Review Board before award commencement. 10. National Lung Cancer Partnership will not discriminate on the basis of gender, race, creed, religion, sexual orientation, disability, nationality, age or any other factor irrelevant to the quality of the application. Award Information The deadline for grant applications is September 2, 2008. Applications must be electronically submitted and postmarked on or before this deadline. Awards will be announced on or before December 15, 2008. The Career Development Award is subject to annual review, and may be granted for a maximum of $50,000 per year for two years. The second year of support is based on the applicant’s demonstration of satisfactory progress.
Contact Us
National Lung Cancer Partnership 222 N. Midvale Blvd., Suite 6 Madison, WI 53705 Phone: 608.233.7905 Fax: 608.233.7893 E-mail: info@NationalLungCancerPartnership.org www.NationalLungCancerPartnership.org
2009 AASLD/ALF Liver Scholar Award Application Deadline: October 16, 2008 Recipient Notification: March 2009 Award Period: July 1, 2009 - June 30, 2012 Appplication coming soon! The AASLD/ALF Liver Scholar Award is a three-year, basic science award of $75,000 per year that endeavors to encourage young investigators to pursue a career in liver-related research. Overview The goal of the Liver Scholar Award is to provide young scientists with support for their research to bridge the gap between completion of research training and attainment of status as an independent research scientist. The additional research experience provided by this award is intended to enable them to successfully compete for research grants from national sources, particularly the NIH. The long-term goal is to attract well-trained investigators, who hold MD, PhD or MD/PhD degrees, to a career in liver disease research. AASLD currently supports a total of five Liver Scholars. Objective These awards are for the purpose of developing the potential of outstanding, young scientists and encouraging research in liver physiology and disease. Therefore, individuals who already are well established in the field are not considered eligible for this award.
American Association for the Study of Liver Diseases 1001 North Fairfax, Suite 400 Alexandria, Virginia 22314 Phone: 703-299-9766 Fax: 703-299-9622 Email: aasld@aasld.org
AAA Postdoctoral Fellowship Program Application deadline: October 1st The AAA Postdoctoral Fellowship, established in 2008, offers salary support to AAA members who are postdoctoral fellows working in any aspect of biology relevant to the anatomical sciences. Either the postdoctoral applicant or the host sponsor (or both) must be a permanent resident of the US or Canada, however, fellowships can be used in any country. Applicants must have been AAA members for one year preceding the application deadline and are expected to remain members for the duration of the fellowship. Candidates should be working on a research project encompassing any aspect of biology that is relevant to the anatomical sciences. Approaches can include (but are not limited to) cellular, molecular, genetic or histological techniques, and/or emphasize development, evolution, morphology or human health.AAA Postdoctoral Fellowship recipients receive: • A $20,000 Fellowship • Travel reimbursement (up to $1,000) plus registration fee to present his/her work at the next appropriate AAA Annual Meeting.
American Association of Anatomists 9650 Rockville Pike Bethesda, Maryland 20814-3998 Tel: 301-634-7910 Fax: 301-634-7965 exec@anatomy.org
Marcel Loncin Research Prize The Marcel Loncin Research Prize, given every other year, was first awarded in 1994. It honors and provides research funding to an IFT member or nonmember scientist or engineer conducting basic chemistry/physics/engineering research applied to food processing and improvement of food quality. The award is sponsored by the Lomi Foundation Endowment Fund of the Institute of Food Technologists.Foundation. AWARD: $50,000 paid in two annual installments and a plaque DEADLINE: December 1, 2009PURPOSE: The prize, given every other year, was first awarded in 1994. To honor and provide research funding for an IFT-member or nonmember scientist or engineer conducting basic chemistry/physics/engineering research applied to food processing and improvement of food quality. Prize money is to be used by the recipient in directing and carrying out a proposed research project, and to allow a successful scientist to help a young scientist(s) to also become successful. ELIGIBILITY: The application must be submitted by an individual eligible to carry out the research; i.e., it is not to be a joint research proposal or a laboratory-manager proposal, although cooperative research is encouraged. The applicant may be from academia, industry, or government, and the organization must verify on the application that it will agree to allow the applicant to work on the proposed research. SPECIAL REQUIREMENTS: The application form must be accompanied by a 5-page grant proposal and a one-page biographical sketch. The proposal should include an introduction with specific objectives, a short critical review of the literature, and a description of the proposed methods. The research proposal must show potential cross-fertilization and cooperation among academia, the food industry, and government organizations where possible. A purely analytical chemistry proposal will not qualify. The recipient of the prize will be announced during the 2010 IFT Annual Meeting. At the 2011 Annual Meeting, the recipient will make an oral, informal progress report at a breakfast/luncheon meeting attended by the confidential research jury. At the 2011 Annual Meeting, the recipient must (1) review the results of his/her study at a breakfast/luncheon meeting attended by the confidential research jury and (2) make an oral presentation of the results of the study as part of the technical program. The recipient must submit an abstract for oral presentation and must make the presentation in person. If appropriate, a Division may sponsor the recipient as a plenary speaker for one of the technical sessions or symposia. RESTRICTIONS: The prize money may not be used exclusively and specifically for purchase of new equipment. Also, the prize money cannot be used for salary for the prize recipient but can be used in part for salary of support personnel or graduate students as long as their work is directly related to the research proposal. Only 10% of the prize may be used for travel expenses and then only for travel to the IFT Annual Meeting. The recipient must agree not to charge any overhead expenses against prize money.
Institute of Food Technologists 525 W. Van Buren, Ste. 1000 Chicago, IL 60607 Phone: 312.782.8424 Fax: 312.782.8348 Email: info@ift.org
Commercialization Grants
Letter of Intent due: AUGUST 1, 2008 If the LOI is accepted, APPLICATION is due: SEPTEMBER 15, 2008 The Epilepsy Therapy Project - Matching Grants Towards the Commercialization of Promising Therapies The Epilepsy Therapy Project offers 1:1 matching grants of up to $100,000 to academic and commercial entities to support the commercialization of novel approaches to the treatment of epilepsy. These matching funds seek to leverage other resources, and accelerate the pace of therapeutic advance. Proposals will be evaluated by our Scientific Advisory Board together with our Business Advisory Board. We seek to fund discrete steps along the commercial pathway that if successful will enable a project to gain further funding. We welcome a broad span of proposals. Examples of the kind of work we would hope to support include: pre-clinical evaluation and testing of compounds or devices with novel mechanisms of action; and early clinical proof-of-principal trials of compounds or devices. Below are some specific project areas identified by our SAB, which illustrate the scope of our interests: Directing a promising therapy towards epilepsy as a clinical pathway for regulatory approval. One example of this is work our founders have done with Cognetix, a Utah-based early stage drug development company utilizing conopeptides. While the company's compound had a number of potential therapeutic uses, the company chose to direct the initial clinical focus for its drug towards epilepsy. Proof-of-principle trials, where a potentially valuable therapy is introduced to selected patients at leading epilepsy centers, under the close watch of leading epileptologists. A case here would be the use of a magnetic stimulation device therapy, which is being carried out in select leading epilepsy centers. Helping to commercialize promising new epilepsy assays, which offer the ability to identify different targets using different mechanisms of action. An example here would be UCB Pharma's levetiracetam (Keppra), a new drug that failed earlier assays, but showed promise when screened with more recent assays. Related to the previous example, we are exploring other promising compounds that have failed earlier assays, but may nonetheless offer value if screened against newer, better assays. While we cannot provide the funds necessary to carry a drug through clinical trials, our funds can help reduce risks in the pre-clinical stage, making subsequent clinical development more feasible. Armed with appropriate pre-clinical data, we can then introduce promising compounds to other investment capital sources for further funding and development. Preference will be given to proposals that already have a commercial partner engaged to assist with development and to proposals that have committed or matched funding from the sponsoring institution, commercial partner or other third party source. Proposals for research originating from outside the United States are welcome. Address questions to grants@epilepsytherapyproject.org. Investigators must submit a Letter of Intent by August 1, 2008. The deadline for receipt of full Grant proposals is September 15, 2008. Full proposals will be accepted only from Investigators whose Letter of Intent was approved.
The Parker B. Francis Fellowship in Pulmonary Research is intended to support the development of outstanding investigators who plan careers in pulmonary research. We seek to help them as they make the transition to independent, self-supporting, faculty members. Parker B. Francis Fellowship grants are awarded to institutions for the purpose of providing stipends, fringe benefits, and modest travel expenses in support of qualified post-doctoral fellows or newly appointed assistant professors. Award recipients will thereby be enabled to devote the major part of their professional effort to research related to pulmonary disease and lung biology. Grants are made for three years of support. It is permissible to maintain support for the awardee as he or she moves from fellowship to faculty status. Awards are made to institutions on behalf of the fellows and can be transferred to other institutions only under special circumstances with prior approval from the Director of the Fellowship Program. Fellows supported by a Parker B. Francis Fellowship must be assured of having at least 75 percent of their time available for research. This means that a total of no more than three months per year may be spent in clinical or other non-research activities.
GENERAL INFORMATION APPLICANTS The ideal candidate is one with evidence of strong aptitude in research and who is in transition from post-doctoral trainee to independent investigator. It is essential that there be evidence of accomplishment and proficiency in research. Few applicants who are just beginning research training and have only one or two research publications are funded. Candidates with greater than seven years since the doctoral degree should include reasons for continued training. Candidates may hold any relevant doctoral degree (e.g., M.D., Ph.D., Sc.D., D.V.M., Dr. P.H.). Fellowships are restricted to US, Canadian and Mexican citizens or permanent residents. However, foreign nationals who document their initial steps toward permanent residence in the US, Canada or Mexico will also be considered. Documentation should include a description of steps already taken toward application for long-term residency or citizenship. MENTORS Mentorship of the fellow by an established investigator is required. Any established faculty scientist at a university or a not-for-profit research institution may mentor a candidate for fellowship. Mentors at government or corporate laboratories are not eligible. The mentor should be in a position to guarantee that 75 percent of a fellow's time is available for research. The mentor should be committed to fostering the candidate's career advancement and should be the primary scientific advisor. Secondary scientific mentors at the same or a different institution are encouraged but not required. Their roles should be described in the body of the application. Many fellows spend some portion of their fellowship years working with a secondary mentor at another institution. INSTITUTIONS There are no restrictions regarding discipline or department. Clinical or basic science departments are suitable; however, it is expected that the proposed research will focus on lung biology or lung disease. Awards are limited to institutions located in the US, Canada and Mexico. Each department may submit only one application annually and is limited to a maximum of two active fellowships at any one time. NOTES ABOUT OTHER GRANT SUPPORT Having an NIH K series or similar award at the time of application makes one ineligible for a PBF Fellowship. However, once awarded, a PBF Fellow may accept such a grant, as long as the basic requirements of the PBF Fellowship are met (75 percent of time available for research and PBF funds used only for salary and travel). Most importantly, the area of lung research pursued should remain the same. Previous individual or institutional NIH or MRC training grants do not make one ineligible, although they must be relinquished if a PBF Fellowship is awarded. Individuals are ineligible for a PBF Fellowship if they are the principal investigator on an NIH RO1 or similar research grant when applying for a PBF Fellowship. But Fellows in their second or third year may have their own NIH RO1 or similar grant. In fact, obtaining research grants is an appropriate goal for PBF Fellows. Since fellowship funds are restricted to the Fellow's salary and travel, in some cases it may not be possible to utilize the full level of PBF Fellowship support. Awards will not be given if either the fellow or mentor currently holds funding from the tobacco industry, even if the tobacco monies will not be used to support the PBF sponsored research. APPROPRIATE TOPICS A broad array of approaches to lung biology and respiratory medicine, ranging from cell and molecular studies, to those involving epidemiologic and clinical aspects of human subjects are appropriate. We also encourage applications from pulmonary medicine specialists interested in pursuing research in bioethical aspects of pulmonary medicine or critical care. Potential topics include, but are not limited to, the ethics of clinical trials in critical care, end-of-life decisions and resource allocation. The context of all these topics should be pulmonary biology and lung disease. Applicants must meet all the eligibility standards. Mentors and/or applicants considering whether a particular area is appropriate are encouraged to discuss potential projects with the Director of the PBF Fellowship Program in Seattle, Washington (trmartin@u.washington.edu).
MAILING ADDRESS Thomas R. Martin, M.D. Director Parker B. Francis Fellowship Program Pulmonary Research Laboratories VA Puget Sound Health Care System 1660 S. Columbian Way, 151L Seattle, WA 98108 DEADLINE Applications must be received no later than Friday, October 17, 2008.
The Talents Program
Letters of Intent (LOI) for the next round of awards are due by August 1, 2008. Disbursements of grants will begin early in January 2009.
The Talents Program has three key aims: Further the understanding of the efficacy and mechanisms of action of IGIV in current clinical indications Explore new clinical uses of IGIV Support the intellectual endeavors of the IGIV research community. Grants are awarded on an annual basis and are usually for either a 1- or 2-year period. Grants can include support for salary, overheads and direct costs. Product may also be provided if requested. The program awards up to $1 million a year. Individual grants can be up to $150,000 per research project per annum, excluding product costs. The maximum funding available per research project is therefore $300,000 awarded over a 2-year period. The funding cycle takes place on an annual basis. Letters of Intent are reviewed in August, funding is determined in October, and funding begins in January of the following year.
How to Apply The Application Process Applications are made in two steps. The first step requires the completion of a Letter of Intent, of which there are two versions: one for basic science projects and one for clinical research projects.
Letters of Intent will be reviewed by The Talents Evaluation Committee, which includes experts in neurology, immunology, hematology, and other disciplines as needed, as well as Talecris scientists. Investigators who submit Letters of Intent that are approved by the Talents Evaluation Committee will be asked to complete a full application form, which will be emailed to those applicants. As with the Letters of Intent, the completed applications will be reviewed by members of the Talents Evaluation Committee; and the committee will determine which proposals will be funded. Each application will be reviewed based on the following set of criteria: Scientific merit Qualifications of applicant Quality of environment Alignment with program goals.
All proposals that meet minimum criteria in the above categories will be ranked and funded until the allotted funds are exhausted.
Who Should Apply? Applications are welcome from individuals with an MD, PhD, DO or PharmD who are affiliated with a facility that utilizes IGIV in a basic or clinical science research setting or to treat patients. Such facilities may include, but are not limited to, universities, hospitals, clinics, blood centers, and laboratories. For-profit organizations are not eligible for funding under the Talents Program, e.g. pharmaceutical companies, homecare companies, health maintenance organizations. If you require additional information, please contact the Program Administrator at: talents@porterhouse.biz.
1234567891011...16next
